Jaguar health announces completion of third-party, investigator-initiated study of crofelemer, which is expected to support orphan drug designation (odd) for crofelemer for congenital diarrheal disorders (cdd)

Study results expected to be described in upcoming presentations and publications cdd patients face intestinal failure (if), similar to patients suffering from short bowel syndrome (sbs) - the priority focus for odd development for crofelemer san francisco, ca / accesswire / february 1, 2022 / jaguar health, inc. (nasdaq:jagx) and napo pharmaceuticals, the company's wholly owned subsidiary, today announced the completion of a third-party, investigator-initiated preclinical enterocyte (intestinal cell) in vitro study to evaluate the effects of crofelemer,napo pharmaceuticals' plant-based prescription drug, on certain genetic defects that result in specific forms of congenital diarrheal disorders. jaguar health believes that these study results will support certain requests received from the office of orphan products development at the u.s. food and drug administration (fda) in response to the orphan drug designation (odd) application napo pharmaceuticals filed with the fda for crofelemer for congenital diarrheal disorders (cdd) in infants and children.
JAGX Ratings Summary
Quant
JAGX Quant Ranking
Sector
Industry
Quant Rating
Quant Score